Bessemer Group’s Fulcrum Therapeutics FULC Stock Holding History

Bessemer Group’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.06M	Sell	285,714 -1,274	-0.4%	-$4.78K	﹤0.01%	945
2026 Q2	$1.05M	Hold	286,988	–	–	﹤0.01%	983
2026 Q1	$2.2M	Hold	286,988	–	–	﹤0.01%	801
2025 Q4	$3.24M	Hold	286,988	–	–	0.01%	612
2025 Q3	$2.64M	Hold	286,988	–	–	﹤0.01%	452
2025 Q2	$1.98M	Hold	286,988	–	–	﹤0.01%	479
2025 Q1	$827K	Hold	286,988	–	–	﹤0.01%	763
2024 Q4	$1.35M	Hold	286,988	–	–	﹤0.01%	711
2024 Q3	$1.02M	Hold	286,988	–	–	﹤0.01%	771
2024 Q2	$1.78M	Hold	286,988	–	–	﹤0.01%	531
2024 Q1	$2.71M	Hold	286,988	–	–	﹤0.01%	474
2023 Q4	$1.94M	Hold	286,988	–	–	﹤0.01%	486
2023 Q3	$1.28M	Hold	286,988	–	–	﹤0.01%	567
2023 Q2	$947K	Hold	286,988	–	–	﹤0.01%	658
2023 Q1	$818K	Hold	286,988	–	–	﹤0.01%	624
2022 Q4	$2.09M	Buy	286,988 +1,274	+0.4%	+$8.31K	0.01%	441
2022 Q3	$2.31M	Hold	285,714	–	–	0.01%	419
2022 Q2	$1.4M	Hold	285,714	–	–	﹤0.01%	512
2022 Q1	$6.76M	Sell	285,714 -23,707	-8%	-$336K	0.01%	238
2021 Q4	$5.47M	Sell	309,421 -1,197	-0.4%	-$23.7K	0.01%	240
2021 Q3	$8.76M	Buy	310,618 +24,904	+9%	+$472K	0.02%	224
2021 Q2	$2.99M	Hold	285,714	–	–	0.01%	283
2021 Q1	$3.37M	Hold	285,714	–	–	0.01%	277
2020 Q4	$3.35M	Hold	285,714	–	–	0.01%	265
2020 Q3	$2.27M	Hold	285,714	–	–	0.01%	314
2020 Q2	$5.23M	Hold	285,714	–	–	0.02%	286
2020 Q1	$3.41M	Hold	285,714	–	–	0.01%	334
2019 Q4	$4.75M	Hold	285,714	–	–	0.02%	348
2019 Q3	$1.9M	Buy	+285,714	New	+$3.16M	0.01%	531

Other funds holding FULC

GSK plc London $497M AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bessemer Group's FULC Position: Q3 2026 in Review

Bessemer Group reduced its Fulcrum Therapeutics (FULC) stake by 0.44% in Q3 2026, selling an estimated $4.78K and leaving 285,714 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #945.

Bessemer Group first reported a position in FULC in Q3 2019 and has held it in 29 quarters since. The position peaked at $8.76M in Q3 2021. 56 funds tracked by Wall St. Rank hold FULC as of Q3 2026.

Bessemer Group held 285,714 shares of Fulcrum Therapeutics worth $1.06M as of Q3 2026.
Bessemer Group sold 1,274 Fulcrum Therapeutics shares in Q3 2026, an estimated $4.78K.
Fulcrum Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q3 2026, its #945 holding.
Bessemer Group first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 29 quarters since.
Bessemer Group's Fulcrum Therapeutics position peaked at $8.76M in Q3 2021.
56 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2026.

Based on Bessemer Group's 13F filing for Q3 2026, filed 9 Nov 2026.